CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results Pharmaceutical Investing
Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency Pharmaceutical Investing
Innovotech Inc. Launches of InnovoTEST Hazardous Drug Wipe Testing Kits to Support Pharmacy Compliance and Healthcare Worker Safety Life Science Investing
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone for Patients with Multiple Myeloma, as Early as First Relapse Life Science Investing
NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026 Life Science Investing
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update Life Science Investing
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update Life Science Investing
Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights Life Science Investing
